Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity

Ophthalmic Surgery Lasers and Imaging

Volumn 38, Issue 3, 2007, Pages 233-237

  Travassos, António ^b   Teixeira, Susana ^a   Ferreira, Pinto ^c   Regadas, Isaura ^b   Travassos, Ana Sofia ^b   Esperancinha, Florindo Esteves ^a   Prieto, Isabel ^a   Pires, Graça ^a   Van Velze, Robert ^b   Valido, A ^d   Machado, Maria Do Céu ^e  

^a HOSPITAL FERNANDO FONSECA   (Portugal)

^b Surgical Center of Coimbra   (Portugal)

^c HOSPITAL DE SÃO JOSÉ   (Portugal)

^d Maternity Dr Alfredo da Costa   (Portugal)

^e High Commissary for Portuguese Health   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; HUMAN; LASER; MONOTHERAPY; NEWBORN; PHYSICAL EXAMINATION; PREMATURITY; PRIORITY JOURNAL; RETINOPATHY; SINGLE DRUG DOSE; TREATMENT OUTCOME;

EID: 34250766682     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/15428877-20070501-09     Document Type: Article

References (28)

1. The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol. 1984;102:1130-1134.
2. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: preliminary results. Arch Ophthalmol. 1988;106:471-479.
3. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: one-year outcome - structure and function. Arch Ophthalmol. 1990;108:1408-1416.
4. Palmer EA, Hardy RJ, Dobson V, et al. 15-year outcomes following threshold retinopathy of prematurity: final results from the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity. Arch Ophthalmol. 2005;123:311-318.
5. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684-1694.
6. McLeod DS, Crone SN, Lutty GA. Vasoproliferative in the neonatal dog model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 1996;37:1322-1333.
7. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92:905-909.
8. Dorey CK, Aouididi S, Reynaud X, Dvorak HF, Brown LF. Correlation of vascular permeability factor/vascular endothelial growth factor with extraretinal neovascularization in the rat. Arch Ophthalmol. 1996;114:1210-1217. Erratum in: Arch Ophthalmol. 1997;115:192.
9. Robbins SG, Conaway JR, Ford BL, Roberto KA, Penn JS. Detection of vascular endothelial growth factor (VEGF) protein in vascular and non-vascular cells of the normal and oxygen-induced rat retina. Growth Factors. 1997;14:229-241.
10. Werdich XQ, McCollum GW, Rajaratnam VS, Penn JS. Variable oxygen and retinal VEGF levels: correlation with incidence with and severity of pathology in a rat model of oxygen-induced retinopathy. Exp Eye Res. 2004;79:623-630.
11. Stone J, Chan-Ling T, Pe'er J, Itin A, Gnessin H, Keshet E. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1996;37:290-299.
12. Leske DA, Wu J, Fautsch MP, et al. The role of VEGF and IGF-1 in a hypercarbic oxygen-induced retinopathy rat model of ROP. Mol Vis. 2004;10:43-50.
13. Young TL, Anthony DC, Pierce E, Foley E, Smith LE. Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity. J AAPOS. 1997;1:105-110.
14. Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A, Rahimi N. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol. 2000;156:1344.
15. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92:10457-10461.
16. Modanlou HD, Gharraee Z, Hasan J, Waltzman J, Nageotte S, Beharry KD. Ontogeny of VEGF, IGF-1 and GH in neonatal rat serum, vitreous fluid and retina from birth to weaning. Invest Ophthalmol Vis Sci. 2006;47:738-744.
17. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26:275-278.
18. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26:354-356.
19. Rosenfeld PL, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
20. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
21. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695 (e1-e15).
22. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006;26:257-261.
23. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-1349.
24. Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci. 2000;41:1217-1228.
25. Saint-Geniez M, D'Amore PA. Development and pathology of the hyaloid, choroidal and retinal vasculature. Int J Dev Biol. 2004;48:1045-1058.
26. Lutty GA, Chan-Ling T, Phelps DL, et al. Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol Vis. 2006;12:532-580.
27. Trese MT, Capone A Jr. Retinopathy of prematurity: evolution of stages 4 and 5 ROP and management. In: Hartnett ME, ed. Pediatric Retina, 1st ed. Philadelphia: Lippincott, Williams & Wilkins; 2005:411-416.
28. McLeod DS, Taomoto M, Cao J, Zhu Z, Witte L, Lutty GA. Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2002;43:474-482.